Top

Published in:

01-04-2018 | Laboratory Investigation

Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma

Authors: Noble Kumar Talari, Manas K. Panigrahi, Sailaja Madigubba, Prakash Babu Phanithi

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor and involved in tumorigenesis of many cancers. However there are no reports on AHR in human meningioma. Therefore we examined the status of the AHR and its signalling molecules in human meningioma by using tumor biopsy samples and autopsy control meninges. We report the up regulation of AHR pathway genes like aryl hydrocarbon receptor nuclear translocator (ARNT), aldehyde dehydrogenase1family memberA3 (ALDH1A3), cytochrome P450, family1, subfamily A polypeptide1 (CYP1A1) and TCCD induced poly ADP ribose polymerase (TIPARP) gene expression in human meningioma. Further, AHR protein expression was found to be up regulated in all grades of human meningioma. We found that AHR localized in the nucleus for high grade anaplastic meningioma through immunohistochemical analysis. Since AHR signalling pathway was known to involve in inhibition of apoptosis in cancer cells, we evaluated the cyclophilin D levels which maintains mitochondrial permeability transition pore a critical event during apoptosis. We report that cyclophilin D levels were upregulated in all grades of human meningioma compared to control meninges. Finally we also evaluated c-Fos protein levels as its levels were regulated by AHR. Here we report that c-Fos protein levels were down regulated in all grades of human meningioma compared to control meninges. To sum-up we found that AHR signalling pathway components were upregulated, as the grade of the meningioma progresses from low to high grade, suggesting an important role of AHR signalling pathway in human meningioma.

Available only for authorised users

Barouki R, Coumoul X, Fernandez-Salguero PM (2007) The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 581:3608–3615. https://doi.org/10.1016/j.febslet.2007.03.046 CrossRefPubMed

Zhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, Liu X, Wilson-Robles H, Safe S (2012) Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Mol Cancer Ther 11:108–118. https://doi.org/10.1158/1535-7163.MCT-11-0548 CrossRefPubMed

Su JM, Lin P, Wang CK, Chang H (2009) Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Anticancer Res 29:509–515PubMed

Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE (2009) The selective aryl hydrocarbon receptor modulator 6-methyl-1, 3, 8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol 77:1151–1160. https://doi.org/10.1016/j.bcp.2008.12.015 CrossRefPubMed

Callero MA, Suarez GV, Luzzani G, Itkin B, Nguyen B, Loaiza-Perez AI (2012) Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. Int J Oncol 41:125–134. https://doi.org/10.3892/ijo.2012.1427 CrossRefPubMed

Yin XF, Chen J, Mao W, Wang YH, Chen MH (2012) A selective aryl hydrocarbon receptor modulator 3, 30-Diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res 31:46. https://doi.org/10.1186/1756-9966-31-46 CrossRefPubMedPubMedCentral

Peng TL, Chen J, Mao W, Liu X, Tao Y, Chen LZ, Chen MH (2009) Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer. World J Gastroenterol 15:1719–1729CrossRefPubMedPubMedCentral

Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197–203. https://doi.org/10.1038/nature10491 CrossRefPubMed

Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185:3190–3198. https://doi.org/10.4049/jimmunol.0903670 CrossRefPubMed

10.

Talari NK, Panigrahi M, Madigubba S, Challa S, Phanithi PB (2016) Altered tryptophan metabolism in human meningioma. J Neurooncol. https://doi.org/10.1007/s11060-016-2225-7 CrossRefPubMed

11.

Perdew GH, Bradfield CA (1996) Mapping the 90 kDa heat shock protein binding region of the Ah receptor. Biochem Mol Biol Int 39:589–593PubMed

12.

Kazlauskas A, Poellinger L, Pongratz I (1999) Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J Biol Chem 274:13519–13524CrossRefPubMed

13.

Enan E, Matsumura F (1996) Identification of c-Src as the integral component of the cytosolic Ah receptor complex, transducing the signal of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) through the protein phosphorylation pathway. Biochem Pharmacol 52:1599–1612CrossRefPubMed

14.

Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR (2009) Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci 112:229–244. https://doi.org/10.1093/toxsci/kfp189 CrossRefPubMedPubMedCentral

15.

Duan JJ, Cai J, Guo YF, Bian XW, Yu SC (2016) ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int J Cancer 139:965–975. https://doi.org/10.1002/ijc.30091 CrossRefPubMed

16.

Whitlock JP Jr (1999) Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39:103–125. https://doi.org/10.1146/annurev.pharmtox.39.1.103 CrossRefPubMed

17.

Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM (2005) Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res 65:3726–3734. https://doi.org/10.1158/0008-5472.CAN-04-3771 CrossRefPubMed

18.

Rodriguez M, Potter DA (2013) CYP1A1 regulates breast cancerproliferation and survival. Mol Cancer Res 11:780–792. https://doi.org/10.1158/1541-7786.MCR-12-0675 CrossRefPubMedPubMedCentral

19.

Zaher H, Fernandez-Salguero PM, Letterio J, Sheikh MS, Fornace AJ Jr, Roberts AB, Gonzalez FJ (1998) The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-beta and apoptosis. Mol Pharmacol 54:313–321CrossRefPubMed

20.

Schubert A, Grimm S (2004) CyclophilinD, a component of the permeability transition-pore, is an apoptosis repressor. Cancer Res 64:85–93CrossRefPubMed

21.

Mejía-García A, González-Barbosa E, Martínez-Guzmán C, Torres-Ramos MA, Rodríguez MS, Guzmán-León S, Elizondo G (2015) Activation of AHR mediates the ubiquitination and proteasome degradation of c-Fos through the induction of Ubcm4 gene expression. Toxicology 337:47–57. https://doi.org/10.1016/j.tox.2015.08.008 CrossRefPubMed

22.

Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde-Langosch K (2008) c-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99:1269–1275. https://doi.org/10.1038/sj.bjc.6604650 CrossRefPubMedPubMedCentral

23.

Bradford MM (1976) A rapid and sensitivemethod for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMed

24.

Sung WW, Lin YM, Wu PR, Yen HH, Lai HW, Su TC, Huang RH, Wen CK, Chen CY, Chen CJ, Yeh KT (2014) High nuclear/cytoplasmic ratio of Cdk1expressionpredictspoorprognosis in colorectal cancer patients. BMC Cancer 14:951. https://doi.org/10.1186/1471-2407-14-951 CrossRefPubMedPubMedCentral

25.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) Method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262 CrossRefPubMed

26.

Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Büchler MW, Friess H (2002) Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 21:6059–6070. https://doi.org/10.1038/sj.onc.1205633 CrossRefPubMed

27.

Gluschnaider U, Hidas G, Cojocaru G, Yutkin V, Ben-Neriah Y, Pikarsky E (2010) beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS ONE 5:e9060. https://doi.org/10.1371/journal.pone.0009060 CrossRefPubMedPubMedCentral

28.

Ishida M, Mikami S, Kikuchi E, Kosaka T, Miyajima A, Nakagawa K, Mukai M, Okada Y, Oya M (2010) Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 31:287 – 95. https://doi.org/10.1093/carcin/bgp222 CrossRefPubMed

29.

Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH (2008) Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem 104:402 – 17. https://doi.org/10.1002/jcb.21630 CrossRefPubMed

30.

Lin P, Chang H, Tsai WT, Wu MH, Liao YS, Chen JT, Su JM (2003) Overexpression of aryl hydrocarbon receptor in humanlungcarcinomas. Toxicol Pathol 31:22–30CrossRefPubMed

31.

Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, Schwarz M, Weller M, Tritschler I (2009) Aryl hydrocarbon receptor inhibition downregulates the TGF-b/Smad pathway in human glioblastoma cells. Oncogene 28:2593–2605. https://doi.org/10.1038/onc.2009.104 CrossRefPubMed

32.

Hayashibara T, Yamada Y, Mori N, Harasawa H, Sugahara K, Miyanishi T, Kamihira S, Tomonaga M (2003) Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun 300:128 – 34CrossRefPubMed

33.

Bosnyak E, Kamson DO, Guastella AR, Varadarajan K, Robinette NL, Kupsky WJ, Muzik O, Michelhaugh SK, Mittal S, Juhász C (2015) Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas. Neuro-oncology 17:1284–1292. https://doi.org/10.1093/neuonc/nov098 CrossRefPubMedPubMedCentral

34.

Zitron IM, Kamson DO, Kiousis S, Juhász C, Mittal S (2013) In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1. Cancer Biol Ther 14:333–339. https://doi.org/10.4161/cbt.23624 CrossRefPubMedPubMedCentral

35.

Stavrinou P, Mavrogiorgou MC, Polyzoidis K, Kreft-Kerekes V, Timmer M, Marselos M, Pappas P (2015) Expression profile of genes related to drug metabolism in human brain tumors. PLoS ONE 10:e0143285. https://doi.org/10.1371/journal.pone.0143285 CrossRefPubMedPubMedCentral

36.

Bui LC, Tomkiewicz C, Chevallier A, Pierre S, Bats AS, Mota S, Raingeaud J, Pierre J, Diry M, Transy C, Garlatti M, Barouki R, Coumoul X (2009) Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity. Oncogene 28:3642–3651. https://doi.org/10.1038/onc.2009.224 CrossRefPubMed

37.

Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S, Behler N, Irmler M, Beckers J, Friess H, Erkan M, Siveke JT, Tannapfel A, Hahn SA, Theis FJ, Esposito I, Kleeff J, Michalski CW (2016) A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut 65:647–657. https://doi.org/10.1136/gutjnl-2014-307616 CrossRefPubMed

38.

Jia J, Parikh H, Xiao W, Hoskins JW, Pflicke H, Liu X, Collins I, Zhou W, Wang Z, Powell J, Thorgeirsson SS, Rudloff U, Petersen GM, Amundadottir LT (2013) An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer. BMC Med Genom 6:33. https://doi.org/10.1186/1755-8794-6-33 CrossRef

39.

Saw YT, Yang J, Ng SK, Liu S, Singh S, Singh M, Welch WR, Tsuda H, Fong WP, Thompson D, Vasiliou V, Berkowitz RS, Ng SW (2012) Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer 12:329. https://doi.org/10.1186/1471-2407-12-329 CrossRefPubMedPubMedCentral

40.

Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW (2011) Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 29:32–45. https://doi.org/10.1002/stem.563 CrossRefPubMed

41.

Nebert DW, Dalton TP, Okey AB, Gonzalez FJ (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279:23847–23850. https://doi.org/10.1074/jbc.R400004200 CrossRefPubMed

42.

Meng FD, Ma P, Sui CG, Tian X, Jiang YH (2015) Association between cytochrome P4501A1 (CYP1A1) genepolymorphisms and the risk of renal cell carcinoma: a meta-analysis. Sci Rep 5:8108. https://doi.org/10.1038/srep08108 CrossRefPubMedPubMedCentral

43.

Ding G, Xu W, Liu H, Zhang M, Huang Q, Liao Z (2013) CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis. Mol Biol Rep 40:3483–3491. https://doi.org/10.1007/s11033-012-2423-0 CrossRefPubMed

44.

Gong FF, Lu SS, Hu CY, Qian ZZ, Feng F, Wu YL, Yang HY, Sun YH (2014) Cytochrome P450 1A1 (CYP1A1) polymorphism and susceptibility to esophageal cancer: an updated meta-analysis of 27 studies. Tumor Biol 35:10351–10361. https://doi.org/10.1007/s13277-014-2341-y CrossRef

45.

Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF (2012) Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep 39:6647–6654. https://doi.org/10.1007/s11033-012-1470-x CrossRefPubMed

46.

Liu L, Wu G, Xue F, Li Y, Shi J, Han J, Zhang X, Na Y, Zhang H, Tang X, Pu H, Yuan Q, Zhang L, Yang M (2013) Functional CYP1A1 genetic variants, alone and in combination with smoking, contribute to development of head and neck cancers. Eur J Cancer 49:2143–2151. https://doi.org/10.1016/j.ejca.2013.01.028 CrossRefPubMed

47.

Teng CS (2000) Proto-oncogenes as mediators of apoptosis. Int Rev Cytol 197:137–202CrossRefPubMed

48.

Mikula M, Gotzmann J, Fischer AN, Wolschek MF, Thallinger C, Schulte-Hermann R, Beug H, Mikulits W (2003) The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene 22:6725–6738. https://doi.org/10.1038/sj.onc.1206781 CrossRefPubMed

49.

Wang X, Gong Y, Wang D, Xie Q, Zheng M, Zhou Y, Li Q, Yang Z, Tang H, Li Y, Hu R, Chen X, Mao Y (2012) Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 over expression in benign meningioma tissue and serum. PLoS ONE 7:e52707. https://doi.org/10.1371/journal.pone.0052707 CrossRefPubMedPubMedCentral

Title: Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma
Authors: Noble Kumar Talari
Manas K. Panigrahi
Sailaja Madigubba
Prakash Babu Phanithi
Publication date: 01-04-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2730-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma

Normalization of ADC does not improve correlation with overall survival in patients with high-grade glioma (HGG)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis

Recursive partitioning analysis is predictive of overall survival for patients undergoing spine stereotactic radiosurgery

A combined diffusion tensor imaging and Ki-67 labeling index study for evaluating the extent of tumor infiltration using the F98 rat glioma model

Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy